Back

Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Predicting outcomes in infective endocarditis Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Assistant Professor Peter Moritz Becher

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

4 More presentations in this session

Presentation thumbnail
Risk calculator to predict 30-day mortality in left-sided infective endocarditis. The EURO-ENDO score
Mr J. Lozano Torres (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: A substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) regist
Doctor Y. Bohbot (Amiens, FR)
Abstract Slides Video
Presentation thumbnail
Factors associated with outcome five years after infectious endocarditis - the POET trial
Doctor M. Pries-Heje (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Infective endocarditis in diabetic patients: a different profile with prognostic
Mrs M. Biezma Lopez (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting outcomes in infective endocarditis

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Epidemiology and temporal trends of infective endocarditis between 2006 and 2018 at a tertiary referral center
thumbnail
Congress Presentation
Epidemiological profile and mortality of infective endocarditis over the past decade: a systematic review and meta-analysis of 133 studies comprising 132,355 cases
thumbnail
Congress Presentation
The main predictors of in-hospital mortality in patients with infective endocarditis: a retrospective single-center study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources